Jaap J. Plomp

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Antisense-mediated exon skipping therapy improves neuromuscular junction deficits in a Duchenne muscular dystrophy mouse model.

Antisense-mediated exon skipping therapy improves neuromuscular junction deficits in a Duchenne muscular dystrophy mouse model.

Journal: Neuromuscular disorders : NMD
Published: August 27, 2025

Structure and function of the neuromuscular junction in health and myasthenia gravis.

Structure and function of the neuromuscular junction in health and myasthenia gravis.

Journal: International review of neurobiology
Published: July 17, 2025

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome.

Journal: Science translational medicine
Published: September 18, 2024

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.

Journal: iScience
Published: July 25, 2024

Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model.

Change of voltage-gated sodium channel repertoire in skeletal muscle of a MuSK myasthenia gravis mouse model.

Journal: The European journal of neuroscience
Published: September 15, 2023

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK.

Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK.

Journal: Scientific reports
Published: January 20, 2023

A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.

A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.

Journal: Journal of neuroscience methods
Published: January 12, 2022

The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model.

The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model.

Journal: Neuromuscular disorders : NMD
Published: November 07, 2021

Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders.

Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders.

Journal: The Lancet. Neurology
Published: May 26, 2021

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.

Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 23, 2021

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy.

Simvastatin Treatment Does Not Ameliorate Muscle Pathophysiology in a Mouse Model for Duchenne Muscular Dystrophy.

Journal: Journal of neuromuscular diseases
Published: October 12, 2020

Time of flight modulation of intensity by zero effort on Larmor.

Time of flight modulation of intensity by zero effort on Larmor.

Journal: The Review of scientific instruments
Published: January 03, 2020
Showing 1-12 of 42

Last Updated: 09/26/2026